Titlebook: Drug Development; Molecular Targets fo Timothy S. Gaginella,Antonio Guglietta Book 2000 Springer Science+Business Media New York 2000 cytok

obstinate

https://doi.org/10.1007/978-3-663-11747-6 the field of animal models of IBD that has occurred in the past decade has considerably expanded the involvement of CKs in intestinal inflammation. Therefore, IBD represents the ideal clinical and experimental model to describe CK abnormalities in the inflamed GI system, and to discuss the related

拾落穗

mosque

撕裂皮肉

Hans-Hermann Braess,Ulrich Seiffert994a, 1994b) and on CCK receptors (Dourish and Hill, 1987; Jensen et al., 1990; Woodruff and Hughes, 1991; Silvente-Poirot et al., 1993; Williams and Blevins, 1993; D’ Amato et al., 1994; Rasmussen, 1995; Wang, 1995) are available. Moreover, Adler and Beglinger (1991), provide comprehensive coverage

凹處

厭煩

The Arachidonic Acid Pathway,. In this chapter, the biological actions of the eicosanoids are reviewed, as are the enzymes through which they are formed, and the receptors through which they act. The potential of drugs that block the activity of these enzymes or the eicosanoid receptors is reviewed, particularly with respect to

myriad

Therapeutic Implications of the Nitric Oxide Pathway in Gastrointestinal Diseases,dies on the role of NO in the GI tract, especially as it relates to maintenance of physiological function and mucosal integrity; the therapeutic potential of agents that modulate the NO system will also be discussed.

改變

negotiable

Peptide Growth Factors in Gastrointestinal Disorder Therapeutics,growth factor-a (TGF-a), for example, in addition to stimulating proliferation of epithelial cells of the gastrointestinal (GI) tract, are also potent inhibitors of gastric acid secretion (Elder et al., 1975; Koffman et al., 1982; Guglietta and Lesch, 1993; Guglietta et al., 1994).

雕鏤